...that OrbusNeich's Combo Bio-engineered Sirolimus Eluting stent met the primary endpoint of non-inferiority to the Taxus Liberte...

...FDA approved the Ion and Taxus Liberte paclitaxel-eluting coronary stent systems from Boston Scientific to treat acute...
...to treat acute myocardial infarction. Both are next-generation drug-eluting coronary platinum chromium alloy stent systems. Taxus Liberte...
...July 14, 1997). Boston Scientific Corp. (NYSE:BSX), Natick, Mass. Product: Ion paclitaxel-eluting coronary stent , Taxus Liberte...

...in the open-label, international Phase II REMEDEE trial to compare its Combo Bio-engineered stent vs. Taxus Liberte...

...Additional data from the ATLAS trial in 871 patients showed that Taxus Liberte and Taxus Express led...
...1997). Angiotech Pharmaceuticals Inc. (TSX:ANP; NASDAQ:ANPI), Vancouver, B.C. Boston Scientific Corp. (NYSE:BSX), Natick, Mass. Product: Taxus Liberte...

...Additional data from the ATLAS Long Lesion study showed that the Taxus Liberte Long Stent significantly reduced...
...were presented at the Transcatheter Cardiovascular Therapeutics meeting in Washington. Boston Scientific previously reported that Taxus Liberte...
...1997). Angiotech Pharmaceuticals Inc. (TSX:ANP; NASDAQ:ANPI), Vancouver, B.C. Boston Scientific Corp. (NYSE:BSX), Natick, Mass. Product: Taxus Liberte...

...Additional data from the ATLAS Small Vessel study showed that Taxus Liberte significantly reduced the rates of...
...of target lesion revascularization (TLR) at 4 years vs. Taxus Express (10.8% vs. 23.8%, p=0.008). Taxus Liberte...
...were presented at the Transcatheter Cardiovascular Therapeutics meeting in Washington. Boston Scientific previously reported that Taxus Liberte...

...international SPIRIT V Diabetes trial in 324 patients with diabetes, Xience V was superior to Taxus Liberte...
...the EuroPCR meeting in Paris. Abbott markets Xience V in the U.S., EU and Japan. Taxus Liberte...

...were no episodes of stent thrombosis in the Nevo arm vs. 2 events in the Taxus Liberte...
...previously reported that the trial met the primary endpoint of in-stent late lumen loss vs. Taxus Liberte...
...Nevo were angina-free at 6 months (see BioCentury, May 25, 2009, & Oct. 5, 2009). Taxus Liberte...

...it submitted an application to FDA to expand the indication of its Taxus Express and Taxus Liberte...

...patents. A third dispute, which was scheduled for a trial in September, alleged Boston Scientific's Taxus Liberte...